LA JOLLA, Calif.--(BUSINESS WIRE)--Nov. 18, 2021--
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its session presentation, focused on non-invasive precision dermatology approaches, at the fifth annual Dermatology Drug Development Summit for Inflammatory Skin Diseases. Held in Boston this year, the Dermatology Drug Development Summit is a prestigious forum committed to overcoming significant R&D hurdles and sharing best practices for advancing efficacious next generation therapies for chronic inflammatory skin conditions.
Presented by Michael D. Howell, PhD, chief scientific officer of DermTech, the session was titled “Non-Invasively Driven Precision Approaches to Personalized Dermatology.” Howell’s presentation evaluated non-invasive skin assessment for personalized dermatology solutions, examined multi-omic analyses in non-invasively collected skin samples, and explored translational medicine applications in biomarker identification and clinical research.
“The Dermatology Drug Development Summit gathers industry leaders and dermatology experts from across the globe to help overcome research and development hurdles for chronic inflammatory skin conditions,” said Howell. “We are honored to be a part of the forum to help drive innovation in precision dermatology.”
DermTech is bringing precision to the practice of dermatology through non-invasive assessment of the skin. The DermTech Smart Sticker™ can be used for biomarker analysis of RNA, DNA, protein, and microbiome. Using the Smart Sticker, cellular material can be collected from the surface of the skin, providing the opportunity to non-invasively identify biomarkers of disease and subgroups of disease, stratify patients based on genomic and proteomic profiles, enrich for responders in a population, and predict and track responses to therapeutic intervention.
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.dermtech.com.
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products, including its platform technology and the Smart Sticker, and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; (9) the ability of DermTech or the Dermatology Drug Development Summit or its participants to overcome research and development hurdles and (10) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10-Q filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118006085/en/
Source: DermTech, Inc.